Markert, JM, Liechty, PG, Wang, W, Gaston, S, Braz, E, Karrasch, M et al. (2009).
Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor
resection for recurrent GBM. Mol Ther 17: 199–207.
Parker, JN, Gillespie, GY, Love, CE, Randall, S, Whitley, RJ and Markert, JM (2000).
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental
murine brain tumors. Proc Natl Acad Sci USA 97: 2208–2213.
Fulci, G, Dmitrieva, N, Gianni, D, Fontana, EJ, Pan, X, Lu, Y et al. (2007). Depletion of
peripheral macrophages and brain microglia increases brain tumor titers of oncolytic
viruses. Cancer Res 67: 9398–9406.
Fulci, G, Breymann, L, Gianni, D, Kurozomi, K, Rhee, SS, Yu, J et al. (2006).
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune
responses. Proc Natl Acad Sci USA 103: 12873–12878.
Currier, MA, Gillespie, RA, Sawtell, NM, Mahller, YY, Stroup, G, Collins, MH et al.
(2008). Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and
combined with cyclophosphamide. Mol Ther 16: 879–885.
Kurozumi, K, Hardcastle, J, Thakur, R, Shroll, J, Nowicki, M, Otsuki, A et al. (2008).
Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61.
Mol Ther 16: 1382–1391.
Kaur, B, Brat, DJ, Devi, NS and Van Meir, EG (2005). Vasculostatin, a proteolytic
fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic
factor. Oncogene 24: 3632–3642.
Zhou, G and Roizman, B (2006). Construction and properties of a herpes simplex
virus 1 designed to enter cells solely via the IL-13alpha2 receptor. Proc Natl Acad Sci
USA 103: 5508–5513.
Kamiyama, H, Zhou, G and Roizman, B (2006). Herpes simplex virus 1 recombinant
virions exhibiting the amino terminal fragment of urokinase-type plasminogen
activator can enter cells via the cognate receptor. Gene Ther 13: 621–629.
Zhou, G and Roizman, B (2005). Characterization of a recombinant herpes simplex
virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells.
J Virol 79: 5272–5277.
Mezhir, JJ, Advani, SJ, Smith, KD, Darga, TE, Poon, AP, Schmidt, H et al. (2005).
Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway
in tumors treated with oncolytic viruses. Cancer Res 65: 9479–9484.
Advani, SJ, Mezhir, JJ, Roizman, B and Weichselbaum, RR (2006). ReVOLT: radiationenhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys 66: 637–646.
Aghi, M, Rabkin, S and Martuza, RL (2006). Effect of chemotherapy-induced DNA
repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 98: 38–50.
Smith, KD, Mezhir, JJ, Bickenbach, K, Veerapong, J, Charron, J, Posner, MC et al.
(2006). Activated MEK suppresses activation of PKR and enables efficient replication
and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol
80: 1110–1120.
Shah, AC, Parker, JN, Gillespie, GY, Lakeman, FD, Meleth, S, Markert, JM et al. (2007).
Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. Gene Ther
14: 1045–1054.
Ganesh, S, Gonzalez-Edick, M, Gibbons, D, Van Roey, M and Jooss, K (2008).
Intratumoral coadministration of hyaluronidase enzyme and oncolytic
adenoviruses enhances virus potency in metastatic tumor models. Clin Cancer Res
14: 3933–3941.
Packer, RJ, Rood, BR and MacDonald, TJ (2003). Medulloblastoma: present concepts
of stratification into risk groups. Pediatr Neurosurg 39: 60–67.
Crawford, JR, MacDonald, TJ and Packer, RJ (2007). Medulloblastoma in childhood:
new biological advances. Lancet Neurol 6: 1073–1085.
Chastagner, P, Kalifa, C, Doz, F, Bouffet, E, Gentet, JC, Ruchoux, MM et al. (2007).
Outcome of children treated with preradiation chemotherapy for a high-grade
glioma: results of a French Society of Pediatric Oncology (SFOP) Pilot Study. Pediatr
Blood Cancer 49: 803–807.
MacDonald, TJ, Arenson, EB, Ater, J, Sposto, R, Bevan, HE, Bruner, J et al. (2005).
Phase II study of high-dose chemotherapy before radiation in children with newly
diagnosed high-grade astrocytoma: final analysis of Children’s Cancer Group Study
9933. Cancer 104: 2862–2871.
Korones, DN, Fisher, PG, Kretschmar, C, Zhou, T, Chen, Z, Kepner, J et al. (2008).
Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy,
vincristine and oral VP-16: a Children’s Oncology Group phase II study. Pediatr Blood
Cancer 50: 227–230.
Dunkel, IJ, Garvin, JH Jr, Goldman, S, Ettinger, LJ, Kaplan, AM, Cairo, M et al. (1998).
High dose chemotherapy with autologous bone marrow rescue for children with
diffuse pontine brain stem tumors. Children’s Cancer Group. J Neurooncol 37:
67–73.
Hargrave, D, Bartels, U and Bouffet, E (2006). Diffuse brainstem glioma in children:
critical review of clinical trials. Lancet Oncol 7: 241–248.
Gidwani, P, Levy, A, Goodrich, J, Weidenheim, K and Kolb, EA (2008). Successful
outcome with tandem myeloablative chemotherapy and autologous peripheral blood
stem cell transplants in a patient with atypical teratoid/rhabdoid tumor of the central
nervous system. J Neurooncol 88: 211–215.
Nazar, GB, Hoffman, HJ, Becker, LE, Jenkin, D, Humphreys, RP and Hendrick, EB
(1990). Infratentorial ependymomas in childhood: prognostic factors and treatment.
J Neurosurg 72: 408–417.
Duffner, PK, Horowitz, ME, Krischer, JP, Friedman, HS, Burger, PC, Cohen, ME et al.
(1993). Postoperative chemotherapy and delayed radiation in children less than
three years of age with malignant brain tumors. N Engl J Med 328: 1725–1731.
Pierre-Kahn, A, Hirsch, JF, Roux, FX, Renier, D and Sainte-Rose, C (1983). Intracranial
ependymomas in childhood. Survival and functional results of 47 cases. Childs Brain
10: 145–156.
Shu, HK, Sall, WF, Maity, A, Tochner, ZA, Janss, AJ, Belasco, JB et al. (2007). Childhood
intracranial ependymoma: twenty-year experience from a single institution. Cancer
110: 432–441.
Sundaresan, P, Hunter, WD, Martuza, RL and Rabkin, SD (2000). Attenuated,
replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in
mice. J Virol 74: 3832–3841.
